alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and oxidopamine
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with oxidopamine in 2 studies
Compound Research Comparison
Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
---|---|---|---|---|---|
90 | 1 | 2 | 8,630 | 6 | 2,407 |
Protein Interaction Comparison
Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | oxidopamine (IC50) |
---|---|---|---|
Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Kamei, H; Kameyama, T; Nabeshima, T | 1 |
Berger, SP; Brudney, EG; Johnson, SW; Meshul, CK; Paquette, MA; Putterman, DB | 1 |
Other Studies
2 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and oxidopamine
Article | Year |
---|---|
SKF-10,047 reverses stress-induced motor suppression: interaction with dopaminergic system.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anticonvulsants; Apomorphine; Dopamine; Electroshock; Guanidines; Male; Methamphetamine; Mice; Mice, Inbred Strains; Motor Activity; Oxidopamine; Pentazocine; Phenazocine; Pimozide; Pyrimidines; Receptors, sigma; Stress, Psychological | 1994 |
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Ligands; Male; N-Methylaspartate; Neurotoxicity Syndromes; Oxidopamine; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors | 2008 |